Generic Name: necitumumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Eli Lilly

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Portrazza is an EGFR inhibitor approved for the first-line treatment of people with metastatic squamous non-small-cell lung cancer (NSCLC) in combination with chemotherapy.

General Info

Portrazza is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR), which is overexpressed in certain cancers. This interferes with the action of EGFR proteins, which play a role in cancer cell growth and development of blood vessels that feed tumors.

A clinical trial showed that Portrazza plus chemotherapy delayed disease progression and improved overall survival in people with metastatic squamous NSCLC being treated for the first time. However, it was not effective for those with nonsquamous NSCLC. Portrazza was first approved in 2015.


Dosing Info:

Portrazza is given by intravenous infusion, usually on two days in a three-week cycle.

Side Effects

Common side effects include skin rash and low magnesium levels. Potential serious side effects may include heart attack due to abnormal electrolyte levels, blood clots, and severe skin reactions and infusion reactions. Portrazza can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: October 23, 2019